Form 4: Lemaitre Vascular Director Accrues Dividend Equivalent Rights
Insider Transaction Report
David B. Roberts, President and Director of Lemaitre Vascular Inc., reported the accrual of various dividend equivalent rights tied to existing equity awards.
Summary
- David B. Roberts, President and Director of Lemaitre Vascular Inc. (LMAT), reported the acquisition of dividend equivalent rights (DERs).
- The transactions occurred on September 4, 2025.
- These DERs accrued on previously granted Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards.
- Each dividend equivalent right is the economic equivalent of one share of Lemaitre Vascular's common stock.
- The DERs vest proportionately with their underlying RSU or PSU awards.
- Specific accruals include: 0.7211 DERs (from 12/2/2020 RSU), 1.3714 DERs (from 12/11/2021 RSU), 2.7926 DERs (from 12/12/2022 RSU), 2.7926 DERs (from 12/12/2022 PSU), 3.5808 DERs (from 12/8/2023 RSU), 4.2906 DERs (from 12/8/2023 PSU), 2.7639 DERs (from 12/6/2024 RSU), and 0.2669 DERs (from 2/18/2025 RSU).
- Following these transactions, Mr. Roberts beneficially owns 17.1959, 25.3792, 34.8043, 34.1213, 25.8906, 27.2657, 9.247, and 0.8937 DERs respectively for each of the aforementioned awards.
Sentiment
Score: 6
Explanation: The accrual of dividend equivalent rights is a standard component of executive compensation, indicating ongoing incentive alignment. It is a neutral to slightly positive event as it reflects continued participation in the company's equity program, though it does not signal new investment or significant operational changes.
Positives
- Accrual of dividend equivalent rights indicates ongoing participation in company performance and aligns executive interests with shareholders.
- The rights are tied to existing equity awards (RSUs and PSUs), suggesting a long-term incentive structure for the executive.
Negatives
- The accrual of dividend equivalent rights, while a form of compensation, can lead to future share dilution when the underlying awards vest and convert to common stock.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This Form 4 filing is a routine disclosure of executive compensation accruals and does not provide specific insights into broader industry trends or the competitive landscape.
Stakeholder Impact
- Shareholders: The accrual of DERs, while part of executive compensation, represents potential future dilution when these rights convert to common stock upon vesting of the underlying awards.
- Management (David B. Roberts): Benefits from increased equity-linked compensation, aligning personal financial interests with the company's long-term performance.
Key Dates
| Date | Description |
|---|---|
| 12/2/2020 | Grant date of Restricted Stock Unit award on which dividend equivalent rights accrued. |
| 12/11/2021 | Grant date of Restricted Stock Unit award on which dividend equivalent rights accrued. |
| 12/12/2022 | Grant date of Restricted Stock Unit award and Performance Share Unit award on which dividend equivalent rights accrued. |
| 12/8/2023 | Grant date of Restricted Stock Unit award and Performance Share Unit award on which dividend equivalent rights accrued. |
| 12/6/2024 | Grant date of Restricted Stock Unit award on which dividend equivalent rights accrued. |
| 2/18/2025 | Grant date of Restricted Stock Unit award on which dividend equivalent rights accrued. |
| 09/04/2025 | Date of transaction for the accrual of dividend equivalent rights. |
| 09/08/2025 | Signature date of the reporting person's representative. |
Keywords
Lemaitre Vascular, LMAT, Form 4, Insider Transaction, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, Executive Compensation, David B. Roberts
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.